A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

BACKGROUND: Sunitinib, a tyrosine kinase inhibitor currently in use for the treatment of metastatic renal cell carcinoma (mRCC), has been reported to modulate immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in addition to exerting anti-angiogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Hirokazu, Enomoto, Yutaka, Kume, Haruki, Nakagawa, Tohru, Fukuhara, Hiroshi, Suzuki, Motofumi, Fujimura, Tetsuya, Homma, Yukio, Kakimi, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331924/
https://www.ncbi.nlm.nih.gov/pubmed/25694811
http://dx.doi.org/10.1186/s40425-014-0030-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331924/
https://www.ncbi.nlm.nih.gov/pubmed/25694811
http://dx.doi.org/10.1186/s40425-014-0030-4

Ejemplares similares